The British journal of ophthalmology · 2018
Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hasegawa Taiji, Murakawa Sakura, Maruko Ichiro, Kogure-Katakura Akiko, Iida Tomohiro
Аннотация
AIM: To determine whether there is a significant correlation between the reduction in macular vessel density and the recurrence of macular oedema in eyes with branch retinal vein occlusion (BRVO).
METHODS: We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in the recurrence group. The macular vessel density in 3×3 mm area centred on the fovea was determined by optical coherence tomography angiography.
RESULTS: At 12 months, 11 of the 27 (40.7%) eyes were placed in the resolved group and the other 16 (59.3%) eyes were placed in the recurrence group. The mean macular vessel density reduction in the resolved group was 17.60%±7.88% and that in the recurrence group was 8.12%±7.48% (P=0.0042). The mean number of IVR injections in the resolved group was 2.1±1.1 and that in the recurrence group was 5.1±1.2 (P<0.0001). In all eyes, multivariate analysis showed that the reduction in macular vessel density was significantly and negatively correlated with the number of IVR injections (β=-0.6746, P=0.0028).
CONCLUSIONS: A reduction in the macular vessel density was significantly correlated with the number of recurrences of macular oedema associated with BRVO.
METHODS: We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in the recurrence group. The macular vessel density in 3×3 mm area centred on the fovea was determined by optical coherence tomography angiography.
RESULTS: At 12 months, 11 of the 27 (40.7%) eyes were placed in the resolved group and the other 16 (59.3%) eyes were placed in the recurrence group. The mean macular vessel density reduction in the resolved group was 17.60%±7.88% and that in the recurrence group was 8.12%±7.48% (P=0.0042). The mean number of IVR injections in the resolved group was 2.1±1.1 and that in the recurrence group was 5.1±1.2 (P<0.0001). In all eyes, multivariate analysis showed that the reduction in macular vessel density was significantly and negatively correlated with the number of IVR injections (β=-0.6746, P=0.0028).
CONCLUSIONS: A reduction in the macular vessel density was significantly correlated with the number of recurrences of macular oedema associated with BRVO.